伴IRF4重排的大B细胞淋巴瘤六例报告及文献复习
单中心收集2017年12月至2021年10月收治的6例伴IRF4重排的大B细胞淋巴瘤患者,行病理学、荧光原位杂交和二代测序检测并复习文献。6例均采用RCDOP方案治疗,随访至2021年11月全部存活;所有病例IRF4重排阳性。作者认为该病为罕见实体,发病机制、治疗选择和长期预后仍需进一步探索。
要点
- 6例患者中男3例、女3例,中位发病年龄33岁,3例起病于扁桃体、2例淋巴结、1例背部肿物。
- 6例均IRF4重排阳性,5例检测BCL6重排中2例阳性,5例检测BCL2和MYC重排均阴性。
- 6例均采用RCDOP方案治疗,随访至2021年11月全部存活。
核心结论
- 伴IRF4重排的大B细胞淋巴瘤是一种具有独特临床、病理学、遗传学特征的罕见大B细胞淋巴瘤。
- 对该类型淋巴瘤的发病机制、治疗选择、长期预后仍需进一步探索。
研究设计与样本
- 单中心收集2017年12月至2021年10月收治的6例伴IRF4重排的大B细胞淋巴瘤患者。
- 对6例患者行病理学、荧光原位杂交和二代基因测序检测,并复习相关文献。
主要发现
- 6例中男3例、女3例,中位发病年龄33岁;3例起病于扁桃体,2例于淋巴结,1例于背部肿物。
- 形态学:5例为弥漫性生长,1例为滤泡性生长,瘤细胞中等至大,病灶多呈膨胀性生长,5例核分裂象易见,6例均未见「星空现象」。
- 免疫组化:4例为生发中心B细胞(GCB)型,2例为非GCB型;6例CD20、PAX5、MUM1、BCL6阳性,CD5阴性;4例CD10阴性,3例BCL2阳性,2例c-MYC阳性。
- 荧光原位杂交:6例IRF4分离探针均阳性;5例检测BCL6基因重排中2例阳性;各5例检测BCL2、MYC基因重排均为阴性。
- 二代测序:3例石蜡组织标本检测到IRF4、TP53、IGLL5、MYD88等淋巴瘤相关基因突变。
临床怎么用
- 6例患者均采用RCDOP(利妥昔单抗、环磷酰胺、脂质体阿霉素、长春新碱、泼尼松)方案治疗,随访至2021年11月全部存活。
- 作者认为该类型淋巴瘤的发病机制、治疗选择、长期预后仍需进一步探索。
局限性
- 作者在结论中指出该类型淋巴瘤的发病机制、治疗选择、长期预后仍需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the clinical, histopathological, and genetic features of large B-cell lymphoma (LBCL) with IRF4 rearrangement. Methods: Six patients presenting at our center between December 2017 and October 2021 were evaluated by pathological examination, fluorescence in situ hybridization, and next-generation sequencing. The relevant literature was reviewed. Results: ①The study sample included three males and three females with a median age of 33 years. Three tumors were in the tonsils, two in the lymphoid nodes, and one in the dorsal lump. All patients were treated using the RCDOP (rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) regimen. All of them were alive at the time of follow-up in November 2021. ②Microscopic examination showed an entirely follicular pattern in one case and an entirely diffused pattern in 5 cases. The tumor cells were medium to large, and most of the lesions were dilatative with brisk mitotic activity (n=five cases) and no starry sky pattern (n=6 cases) . ③Four cases exhibited a GCB phenotype, and the other two exhibited a non-GCB phenotype. All of the cases were positive for CD20, PAX-5, MUM, and BCL6, and negative for CD5. Moreover, CD10, BCL2, and c-MYC were positive in 4, 3, and 2 cases, respectively.④IRF4 gene rearrangement was identified in all cases, BCL6 gene rearrangement was detected in 5 cases, and 2 cases were positive. BCL2 and MYC gene rearrangement were performed in 5 cases, all negative. ⑤Three paraffin tissue samples were used for next-generation sequencing, and lymphoma-related gene mutations such as IRF4, TP53, IGLL5, and MYD88 were detected in 3 cases. Conclusions: LBCL with IRF4 rearrangement is a rare entity with unique clinical, pathological, and genetic characteristics. This entity's pathogenesis, treatment options, and long-term prognosis still need to be explored further. 目的: 探讨伴1RF4重排的大B细胞淋巴瘤的临床、病理学、遗传学特征。 方法: 收集中国医学科学院血液病医院淋巴瘤诊疗中心2017年12月至2021年10月收治的6例伴1RF4重排的大B细胞淋巴瘤患者的临床资料,包括病理学、荧光原位杂交、二代基因测序检测,并复习相关文献。 结果: ①6例患者中男3例,女3例,中位发病年龄33岁。6例患者中3例起病部位为扁桃体,2例为淋巴结,1例为背部肿物。6例患者均采取了RCDOP(利妥昔单抗、环磷酰胺、脂质体阿霉素、长春新碱、泼尼松)方案治疗,随访至2021年11月,6例患者全部存活。②形态学:5例为弥漫性生长,1例为滤泡性生长,瘤细胞体积均为中等至大,病灶多呈膨胀性生长,5例核分裂象易见,6例均未见"星空现象"。③免疫组化:4例为生发中心B细胞(GCB)型,2例为non-GCB型;6例均为CD20、PAX5、MUM1、BCL6阳性,CD5阴性;4例CD10阴性;3例BCL2阳性,2例c-MYC阳性。④荧光原位杂交:6例患者IRF4分离探针检测均呈阳性;5例进行BCL6基因重排检测,2例重排阳性;各有5例进行了BCL2、MYC基因重排检测,均为阴性。⑤二代测序:3例患者应用石蜡组织标本进行了二代测序,可见IRF4、TP53、IGLL5、MYD88等淋巴瘤相关基因突变。 结论: 伴IRF4重排的大B细胞淋巴瘤是一种具有独特临床、病理学、遗传学特征的罕见的大B细胞淋巴瘤。对该类型淋巴瘤的发病机制、治疗选择、长期预后仍需进一步探索。.
引用
- Yu Y, Sun Q, Li CW, et al. [Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35968590. doi:10.3760/cma.j.issn.0253-2727.2022.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。